Current checkpoint inhibitors each have a rundown cost close $150,000 every year. A mix of Yervoy and Opdivo, endorsed by the Food and Drug Administration for cutting edge or inoperable melanoma, has an expense of $256,000 every year for patients who react to the treatment.